Weisser NE, Wickman G, Abraham L et al (2021) Abstract 1005: the bispecific antibody zanidatamab’s (ZW25’s) unique mechanisms of action and durable anti-tumor activity in HER2-expressing cancers. Cancer Res 81:1005–1005. https://doi.org/10.1158/1538-7445.AM2021-1005

Article  Google Scholar 

Hausman DF, Hamilton EP, Beeram M et al (2017) Phase 1 study of ZW25, a bispecific anti-HER2 antibody, in patients with advanced HER2-expressing cancers. J Clin Oncol 35:TPS215–TPS215

Article  Google Scholar 

Weisser N, Wickman G, Davies R, Rowse G (2017) abstract 31: preclinical development of a novel biparatopic her2 antibody with activity in low to high her2 expressing cancers. in: experimental and molecular therapeutics. Am Assoc for Cancer Res. https://doi.org/10.1158/1538-7445.AM2017-31

Article  Google Scholar 

Oh D-Y, Hamilton E, Hanna D et al (2019) Safety, anti-tumour activity, and biomarker results of the HER2-targeted bispecific antibody ZW25 in HER2-expressing solid tumours. Ann Oncol. https://doi.org/10.1093/annonc/mdz420

Article  PubMed  PubMed Central  Google Scholar 

Meric-Bernstam F, Hamilton EP, Beeram M et al (2021) Zanidatamab (ZW25) in HER2-expressing gastroesophageal adenocarcinoma (GEA): results from a phase I study. J Clin Oncol 39:164–164. https://doi.org/10.1200/JCO.2021.39.3_suppl.164

Article  Google Scholar 

Meric-Bernstam F, Hanna DL, El-Khoueiry AB et al (2021) Zanidatamab (ZW25) in HER2-positive biliary tract cancers (BTCs): results from a phase I study. J Clin Oncol 39:299–299. https://doi.org/10.1200/JCO.2021.39.3_suppl.299

Article  Google Scholar 

Bedard PL, Im S-A, Elimova E et al (2022) Abstract P2–13–07: Zanidatamab (ZW25), a HER2-targeted bispecific antibody, in combination with chemotherapy (chemo) for HER2-positive breast cancer (BC): Results from a phase 1 study. Cancer Res. https://doi.org/10.1158/1538-7445.SABCS21-P2-13-07

Article  Google Scholar 

Ku G, Elimova E, Denlinger CS et al (2021) 1380P Phase (Ph) II study of zanidatamab + chemotherapy (chemo) in first-line (1L) HER2 expressing gastroesophageal adenocarcinoma (GEA). Ann Oncol 32:S1044–S1045. https://doi.org/10.1016/j.annonc.2021.08.1489

Article  Google Scholar 

Tabernero J, Hoff PM, Shen L et al (2018) Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study. Lancet Oncol 19:1372–1384. https://doi.org/10.1016/S1470-2045(18)30481-9

CAS  Article  PubMed  Google Scholar 

Janjigian YY, Kawazoe A, Yañez P et al (2021) The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature 600:727–730. https://doi.org/10.1038/s41586-021-04161-3

CAS  Article  PubMed  PubMed Central  Google Scholar 

Meric-Bernstam F, Beeram M, Mayordomo JI et al (2018) Single agent activity of ZW25, a HER2-targeted bispecific antibody, in heavily pretreated HER2-expressing cancers. J Clin Oncol 36:2500–2500. https://doi.org/10.1200/JCO.2018.36.15_suppl.2500

Article  Google Scholar 

Quartino AL, Li H, Kirschbrown WP et al (2019) Population pharmacokinetic and covariate analyses of intravenous trastuzumab (Herceptinl), a HER2-targeted monoclonal antibody, in patients with a variety of solid tumors. Cancer Chemother Pharmacol 83:329–340. https://doi.org/10.1007/s00280-018-3728-z

CAS  Article  PubMed  Google Scholar 

Fukushima Y, Charoin J-E, Brewster M, Jonsson N (2007) Population pharmacokinetic analysis of trastuzumab (Herceptin®) based on data from three different dosing regimens. Copenhagen

Han K, Jin J, Maia M et al (2014) Lower exposure and faster clearance of bevacizumab in gastric cancer and the impact of patient variables: analysis of individual data from AVAGAST phase III trial. AAPS J 16:1056–1063. https://doi.org/10.1208/s12248-014-9631-6

CAS  Article  PubMed  PubMed Central  Google Scholar 

Osawa M, Hasegawa M, Bello A et al (2019) population pharmacokinetics analysis of nivolumab in asian and non-asian patients with gastric and gastro-esophageal junction cancers. Cancer Chemother Pharmacol 83:705–715. https://doi.org/10.1007/s00280-019-03771-z

CAS  Article  PubMed  Google Scholar 

Garg A, Quartino A, Li J et al (2014) Population pharmacokinetic and covariate analysis of pertuzumab, a HER2-targeted monoclonal antibody, and evaluation of a fixed, non-weight-based dose in patients with a variety of solid tumors. Cancer Chemother Pharmacol 74:819–829. https://doi.org/10.1007/s00280-014-2560-3

CAS  Article  PubMed  Google Scholar 

Ahamadi M, Freshwater T, Prohn M et al (2017) model-based characterization of the pharmacokinetics of pembrolizumab: a humanized anti-pd-1 monoclonal antibody in advanced solid tumors. CPT Pharmacomet Syst Pharmacol 6:49–57. https://doi.org/10.1002/psp4.12139

CAS  Article  Google Scholar 

Shemesh CS, Chanu P, Jamsen K et al (2019) Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer. J Immunother Cancer 7:314. https://doi.org/10.1186/s40425-019-0791-x

Article  PubMed  PubMed Central  Google Scholar 

Ryman JT, Meibohm B (2017) pharmacokinetics of monoclonal antibodies. CPT Pharmacomet Syst Pharmacol 6:576–588. https://doi.org/10.1002/psp4.12224

CAS  Article  Google Scholar 

Kim J, Hayton WL, Robinson JM, Anderson CL (2007) Kinetics of FcRn-mediated recycling of IgG and albumin in human: pathophysiology and therapeutic implications using a simplified mechanism-based model. Clin Immunol Orlando Fla 122:146–155. https://doi.org/10.1016/j.clim.2006.09.001

CAS  Article  Google Scholar 

Baverel PG, Dubois VFS, Jin CY et al (2018) Population pharmacokinetics of durvalumab in cancer patients and association with longitudinal biomarkers of disease status. Clin Pharmacol Ther 103:631–642. https://doi.org/10.1002/cpt.982

CAS  Article  PubMed  PubMed Central  Google Scholar 

Mo G, Baldwin JR, Luffer-Atlas D et al (2018) population pharmacokinetic modeling of olaratumab, an anti-pdgfrα human monoclonal antibody, in patients with advanced and/or metastatic cancer. Clin Pharmacokinet 57:355–365. https://doi.org/10.1007/s40262-017-0562-0

CAS  Article  PubMed  Google Scholar 

Freshwater T, Kondic A, Ahamadi M et al (2017) Evaluation of dosing strategy for pembrolizumab for oncology indications. J Immunother Cancer 5:43. https://doi.org/10.1186/s40425-017-0242-5

Article  PubMed  PubMed Central  Google Scholar 

Novakovic AM, Wilkins JJ, Dai H et al (2020) changing body weight-based dosing to a flat dose for avelumab in metastatic merkel cell and advanced urothelial carcinoma. Clin Pharmacol Ther 107:588–596. https://doi.org/10.1002/cpt.1645

CAS  Article  PubMed  Google Scholar 

Zhao X, Suryawanshi S, Hruska M et al (2017) Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors. Ann Oncol Off J Eur Soc Med Oncol 28:2002–2008. https://doi.org/10.1093/annonc/mdx235

CAS  Article  Google Scholar